tbuckley/cabot-search huggingface dataset:
Church service: President's address
Authors: Christopher Paine
Journal: Journal of the Royal Society of Medicine (1998)

After medical school at Oxford and St Bartholomew's Hospital, Sir Christopher Paine was Consultant in Radiotherapy and Oncology at Oxford from 1970–1995. From 1982–1985 he was Director of Clinical Studies of the Oxford University Medical School and District General Manager of Oxfordshire Health Authority from 1984–1988. Sir Christopher was then President of The Royal College of Radiologist from 1992–1995, and Vice Chairman of the Conference of Medical Royal Colleges for the year 1994/1995. From July 1996 until July 1998 he was the President of The Royal Society of Medicine. His present post is Medical Director of the Advisory Committee on Distinction Awards. In 1995, he was knighted in the New Year Honours.
Decitabine In Advanced Chronic Myelomonocytic Leukemia
Authors: Valeria Santini, Bernardino Allione, Alessandro Levis, Daniela Gioia, Monia Lunghi, Antonella Poloni, Daniela Cilloni, Gina Zini, Alessandro Sanna, Alessia Rossi, Adelmo Terenzi, Emanuele Angelucci, Carlo Finelli, Francesco Onida, Giuseppe Rossi, Dario Ferrero, Giuseppe Saglio, Elisa Masiera
Journal: Blood (2013)
An Acquired Mutation in Deubiquitinating Enzyme USP11 Associated with Clonal Hematopoiesis in Diamond Blackfan Anemia
Authors: Nieves Perdigones, Daria V. Babushok, Lifeng Tian, Jonathan Bradfield, Cecilia E Kim, Juan C. Perin, Hakon Hakonarson, Monica Bessler, Philip J Mason
Journal: Blood (2014)
TCTAP C-243 Percutaneous Retrieval of Migrated Atrial Septal Defect Occluder After Implantation of Device
Authors: Sang Jin Ha, Won-Kyung Lee, Yeo-Jeong Song, Woo Dae Bang, Sang-Yong Yoo, Sangsig Cheong
Journal: Journal of the American College of Cardiology (2016)
TCTAP C-208 Successful Treatment for Acute Thrombotic Occlusion in Superficial Femoral Artery Stent Using Angio Sculpt PTA Balloon
Authors: Hideaki Otsuji, Ippei Kosedo, Yutaro Nomoto, Masanori Tsurugida, Koichi Kihara
Journal: Journal of the American College of Cardiology (2016)
A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH cells via the kinase TBK1
Authors: Christophe Pedros, Yaoyang Zhang, Joyce K Hu, Youn Soo Choi, Ann J Canonigo-Balancio, John R Yates, Amnon Altman, Shane Crotty, Kok-Fai Kong
Journal: Nature Immunology (2016)
Prevalence of BRCA1 mutations among 284 women with triple-negative breast cancer.
Authors: F. Fostira, M. Tsitlaidou, H. Gogas, M. Pertesi, D. Yannoukakos, E. Bournakis, V. Karavassilis, P. Skarlos, I. Konstantopoulou, G. Fountzilas
Journal: Journal of Clinical Oncology (2010)

1511 Background: Triple-negative breast cancer (TNBC) is a type of aggressive breast cancer diagnosed in approximately 15% of total breast cancer patients. TNBCs are characterised by the lack of expression of estrogen receptors alpha (ER-α), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2), and thus are unresponsive to currently available ER-targeted and HER2-based treatments. An intriguing characteristic of TNBC is its association with hereditary breast cancers, as TNBCs are over-represented in BRCA1 mutation carriers. The etiology behind this association is yet unclear but may ultimately provide avenues for prevention and targeted therapy. Screening for BRCA1 and BRCA2 mutations is now an established component of risk evaluation and management of hereditary breast cancer. Genetic testing is offered to a breast cancer patient usually according to her family history; however some women may qualify for testing solely because of an early age of onset and/or tumor pathology, such as the triple-negative phenotype. There is a lack of population studies that determine the frequency of BRCA1 mutations among TNBC patients. Methods: We studied 284 women who were diagnosed with triple-negative invasive breast cancer independently of their age or family history. The mean age for the total cohort was 50.4 years (range: 21-76). The most prevalent BRCA1 mutations in the Greek population that account for 54% of all mutations detected in both genes (BRCA1 and BRCA2), were screened in all patients. Additionally, BRCA1 exons 5, 11 and 23 were also sequenced in cases with age of onset < 40 years. Results: Thirty deleterious BRCA1 mutations were identified in the 284 patients with triple-negative breast cancer (10.6%). Mean age of onset for all mutation carriers was 40.2 years (range: 28-57). Of the 30 carriers, 10 had no reported family history of breast or ovarian cancer. Among a total of 36 women with early-onset TNBC (< 40 years), 17 (47%) had a BRCA1 mutation. Conclusions: Women with early-onset triple-negative breast cancer are candidates for genetic testing for BRCA1, even in the absence of a family history of breast or ovarian cancer. No significant financial relationships to disclose.
Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting.
Authors: J. R. Hoverman, S. K. Gruschkus, C. E. Muehlenbein, M. T. Forsyth, C. Chen, A. H. Lawson, G. Pohl
Journal: Journal of Clinical Oncology (2010)

6137 Background: The purpose of this retrospective study was to evaluate the impact of comorbidities on clinical/economic outcomes among advanced NSCLC patients (pts) receiving care within a large network of outpatient community-based oncology clinics. Methods: US Oncology's iKnowMed EMR data were used to identify NSCLC pts initiating first- or second-line chemotherapy regimens from 7/1/06-12/31/08. EMR data were searched for documentation of the following comorbidities: moderate/severe renal disease, congestive heart failure (CHF), dementia, COPD, cerebrovascular disease, paralysis, diabetes, peripheral vascular disease (PVD), myocardial infarction, liver disease, and AIDS. The Charlson comorbidity index was applied to categorize pts by number and severity of conditions. Pts were followed through 6/30/09 to observe overall/progression-free survival (OS/PFS) and outpatient costs. Claims data were used to estimate outpatient cost of care and resource utilization (frequency of outpatient visits, acute care visits, chemotherapy infusions, and laboratory procedures). Kaplan-Meier/Cox proportional hazards regression analyses were used to compare OS/PFS by comorbidity status. Log-level multiple regression analyses were used to compare costs/resource utilization. Potential covariates included stage, line of therapy, and practice characteristics. Results: 2,513 NSCLC pts receiving first-line (2,004) and second-line (509) care were identified during the study period. Overall prevalence of comorbidities was 22%; the most common conditions were COPD, diabetes, PVD, and CHF. Comorbid burden was not associated with OS or PFS. However, pts with the highest comorbid burden (comorbidity index 2+) had higher outpatient costs (12% increased cost relative to pts with no comorbidities, p < 0.001) and also had a 10% increased frequency of outpatient visits (p = 0.01) and a 17% increased frequency of laboratory procedures (p < 0.001) after controlling for stage and line of therapy. Conclusions: Results of this study suggest that comorbidities impact economic but not clinical outcomes among advanced NSCLC patients in the outpatient setting. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Lilly
Abstract 12007: Combination Therapy of Eicosapentaenoic Acid and Pitavastatin for Coronary Plaque Regression Evaluated by Integrated Backscatter Intravascular Ultrasonography: A Randomized Controlled Trial
Authors: Kaoru Ando, Tetsu Watanabe, Hyuma Daidoji, Yoichiro Otaki, Naoto Hashimoto, Yu Kumagai, Naoaki Hashimoto, Taro Narumi, Shinpei Kadowaki, Gensai Yamaura, Masahiro Wanezaki, Akira Funayama, Yoshinori Yashiro, Tadateru Iwayama, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Tetsuro Shishido, Takuya Miyamoto, Isao Kubota
Journal: Circulation (2015)

Introduction: High intensity statin therapy is established for secondary prevention of coronary heart disease (CHD). However, additional therapy is required to reduce residual risk in CHD patients with aggressive lipid-lowering therapy. Eicosapentaenoic acid (EPA) was reported to be beneficial especially in secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by additional administration of EPA to high dose pitavastatin (PTV) therapy. Methods: We enrolled 200 CHD patients who underwent percutaneous coronary intervention in 6 hospitals. Patients were randomly allocated to PTV group (PTV 4 mg/day, n=98) and PTV/EPA group (PTV 4 mg/day and EPA 1800 mg/day, n=102), and prospectively followed for 6 to 8 months. Coronary plaque volume and composition in non-stenting lesion were analyzed by integrated backscatter intravascular ultrasonography at baseline and follow up. Results: EPA / arachidonic acid (AA) ratio was significantly increased in PTV/EPA group compared to PTV group at follow up period. Plaque volume and lipid volume were significantly reduced in PTV/EPA group, but not PTV group. There was a significant inverse correlation between change in EPA/AA ratio and changes in plaque volume (r=-0.332, p&lt;0.001). Plaque regression was defined as percent change in plaque volume more than -14.6% according to previous reports. A multivariate logistic analysis demonstrated that the additional administration of EPA was independently associated with plaque regression after adjustment of confounding factors. The prevalence rate of plaque regression was significantly higher in PTV/EPA group than in PTV group (50% vs. 24%, p&lt;0.001). Conclusions: Additional administration of EPA to high dose PTV therapy significantly reduced coronary plaque volume, suggesting that combination therapy of EPA and PTV might reduce residual risk in CHD patients with aggressive lipid-lowering therapy.
Case 41-1965
Authors: Harold L. Israel, Benjamin Castleman
Journal: New England Journal of Medicine (1965)

Presentation of Case*A thirty-four-year-old man was admitted to the hospital because of pain and swelling in the right parotid gland.Three weeks previously he experienced the onset of pain in the lower portion of the jaw on the right side. One week later a right lower molar tooth was extracted in a dentist's office under thiopental anesthesia; no evidence of infection of the tooth was observed by the dentist. Four days after the extraction the right side of the face became swollen, and the pain increased in severity. An x-ray film of the chest was interpreted as showing a . . .
ATPS-96HISTONE DEACETYLASE INHIBITORS REPRESS HYPOXIA SIGNALING THROUGH AFFECTING HSP90
Authors: Chunzhang Yang, Chao Zhang, Michael Feldman, Pauline Dmitriev, Zhengping Zhuang
Journal: Neuro-Oncology (2015)

Histone deacetylase inhibitors (HDACis) are among the most promising recently developed anti-cancer agents.Recent work suggests that HDACis suppress both malignant cell metabolism and progression by interfering with the hypoxia-inducible factor (HIF) signaling, which plays a key role in tumor progression in both actual and falsely perceived cellular hypoxia (pseudohypoxia).However, the precise biochemical mechanism of HDACis repression of HIFs function remains unclear.In this study, we demonstrated that the class-2 histone deacetylase inhibitor SAHA potently inhibits hypoxia signaling via interfering with heat shock protein 90 (Hsp90).HDACis increase in the acetylation of Hsp90, resulting in less HIF-a recognition and nuclear translocation.Accumulated cytoplasmic HIF-a is not transcriptional active and degradaded through proteosomal pathway.Finally, we demonstrated that SAHA remarkably reduce hypoxia signaling and decrease tumor growth in vivo.These findings provide insight into new possible therapeutic strategies for using HDACis in tumors with known HIF pathway aberrations.
Helper Factor(s) Generated by Tumor-Immune Rats for Lymphoproliferative Responses to Syngeneic Tumor Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: M A Hollingsworth, D L Evans
Journal: JNCI Journal of the National Cancer Institute (1984)

New Zealand Black ( NBR ) rats that are innately immune to challenge with a syngeneic 3-methylcholanthrene [(MCA) CAS: 56-49-5]-induced fibrosarcoma have spleen cells that produce helper effects for in vitro lymphoproliferative responses in the presence of individual MCA-induced fibrosarcoma cells. Spleen cells from MCA-induced fibrosarcoma progressor rats (which lack innate tumor immunity) do not produce demonstrable helper activity. Supernatants from 48-hour cocultures of spleen cells from tumor-immune (TI) rats and syngeneic MCA-induced fibrosarcoma cells replaced the spleen cell helper activity. Comparable spleen cell supernatants from tumor progressor rats or unchallenged rats (controls) as well as supernatants from MCA-induced fibrosarcoma cells cultured alone did not produce any helper factor activity. Supernatants from TI rat spleen cells following inoculation with MCA-induced fibrosarcoma cells did not affect lymphoproliferative responses of NBR spleen cells induced by concanavalin A or alloantigens. The supernatants also did not contain detectable interleukin 2 activity as determined with the use of the thymocyte costimulator assay. These data indicate that the production of soluble helper factors by TI rat spleen cells may be involved in the augmentation of a protective host antitumor response.
Research funds should be returned if findings can’t be reproduced, proposes Merck chief
Authors: Susan Mayor
Journal: BMJ (2016)

Universities should return funding from the industry for research that proves to be non-reproducible, the chief medical officer of the drug company Merck has said in a proposal to reduce research that cannot be replicated by others.

“Recent studies have shown that the key findings in 50% or more of published reports in certain fields cannot be reproduced,” wrote Michael …
TCTAP C-161 Ankylosing Spondyliti, III Stage Complications: Secondary Heart and Renal Amyloidosis, CHF III, FC IV by NYHA, Nephrotic Syndrome, CRF, Compensatory Phase, Ascites and Pleural Effusion
Authors: Mirzo Juraev, Anvar Bozorov
Journal: Journal of the American College of Cardiology (2016)
Cytochemical Study on Uptake of Exogenous Peroxidase by Vx2 Carcinoma Cells Transplanted Into the Rabbit2
Authors: Chuzo Morimoto
Journal: JNCI Journal of the National Cancer Institute (1978)

When horse-radish peroxidase (HPO) was administered iv to Vx2 carcinoma-bearing rabbits, an HPO reaction product was detected in the lumina of blood vessels and the extracellular spaces between tumor cells in the first few minutes after administration. HPO was also seen in vesicles in tumor cells. Fifteen minutes to 1 hour after administration, the HPO reaction product was found mainly in the large membrane-bound vacuoles. Within 6--12 hours, the HPO activity gradually diminished in large membrane-bound vacuoles (lysosomes). In conclusion, exogenous HPO was rapidly incorporated into Vx2 carcinoma cells by pinocytosis, and then pinocytotic vesicles were fused with lysosomes.
Muscular Subaortic Stenosis: Effect of Peripheral Vasodilatation
Authors: E D WIGLE, S C LENKEI, A CHRYSOHOU, D R WILSON
Journal: JAMA (1963)

Amyl nitrite was administered on two occasions to a patient with muscular subaortic stenosis, to ascertain if selective peripheral vasodilatation would affect the degree of obstruction to left ventricular outflow in this condition. On each occasion there was a marked increase in the systolic pressure gradient across the left ventricular outflow tract prior to the onset of reflex tachycardia. Following the second amyl nitrite inhalation, the systolic cross-sectional area of the left ventricular outflow tract decreased to 1.0 sq. cm., from the control value of 2.6 sq. cm. It is believed that the increased degree of muscular subaortic stenosis, following peripheral vasodilatation, could be secondary to a decrease in the systolic size of the whole left ventricle, or to a selective decrease in the physical size of the left ventricular outflow tract.
A Lone Walk
Authors: Ingmar Skoog
Journal: BMJ (2001)

Gul Y Davis 

Tindal Street Press, £6.99, pp 119

ISBN 0 9535895 3 6

Rating: ![Graphic][1] ![Graphic][2] ![Graphic][3] ![Graphic][4] 

Wil is running and running and running. Running from the cold, unemotional, sometimes even brutal psychiatric wards where he has spent the last couple of years. He is running from himself, his anxiety, his emotional scares. He is running from his mother and everyone else who is trying to put him into a little box. All he wants is love …

 [1]: /embed/inline-graphic-1.gif
 [2]: /embed/inline-graphic-2.gif
 [3]: /embed/inline-graphic-3.gif
 [4]: /embed/inline-graphic-4.gif
SURG-13THE IMPACT OF MULTIMODAL FUNCTIONAL AND METABOLIC IMAGING OF HIGHLY-ELOQUENT BRAIN TUMORS ON FUNCTIONAL OUTCOME AND EXTENT OF RESECTION
Authors: Andrea Faymonville, Catharina Schröter, Gabriele Stoffels, Christian Grefkes, Roland Goldbrunner, Carolin Wei Lucas
Journal: Neuro-Oncology (2015)

SURG-13. THE IMPACT OF MULTIMODAL FUNCTIONAL AND METABOLIC IMAGING OF HIGHLY-ELOQUENT BRAIN TUMORS ON FUNCTIONAL OUTCOME AND EXTENT OF RESECTION Andrea Faymonville1, Catharina Schroter1, Gabriele Stoffels2, Christian Grefkes2,3, Roland Goldbrunner1, and Carolin Wei Lucas1; Department of Neurosurgery, University of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; Department of Neurology, University of Cologne, Cologne, Germany INTRODUCTION: Since functional outcome and extent of resection are of crucial importance for the adjuvant treatment and quality of life of patients with eloquently located gliomas, preoperative metabolic and functional imaging helps to delineate metabolically active and functionally relevant tumor parts. Here, the impact of multimodal preoperative imaging on functional outcome and extent of resection was prospectively investigated. METHODS: 54 patients with high grade gliomas (IV8: N 1⁄4 46; III8: N 1⁄4 8) adjacent to the primary motor cortex or the pyramidal tract were allocated to threegroups for matchedpair analysis.GroupM (“multimodal”)was investigated by navigated transcranial magnetic stimulation (nTMS), functional MRI, DTI tractography and O-(2-[18F]Fluoroethyl)-L-tyrosine positron emission tomography (FET-PET) prior to surgery. Group T (“nTMS”) received preoperative nTMS and FET-PET while patients of group S (“standard”) were operated based on contrast-enhanced MRI. Intraoperatively, fluorescence-guidance (5-aminolevolinic acid), neuronavigation and direct cortical stimulation were applied in all groups. Motor function was assessed before surgery and at discharge. Any residual contrast enhancement in the postoperative MRI scan (0-48 hrs. after surgery) was regarded as tumor residual. RESULTS: 52% of the patients had preoperative motor deficits. At discharge, the paresis had improved in 26%, worsened in 7% and remained unchanged in 63%. Tumor size, localization and hemispheric dominance were even in all groups. Distance of tumor to the primary motor cortex/ pyramidal tract was significantly shorter in groups M/T compared to group S. Functional outcome was not significantly different between groups. The rate of complete resections was higher in groups M/T. Moreover, the predictability of the resection extent by the surgeons was significantly higher in those groups. CONCLUSION: Preoperative metabolic and functional imaging of motor-eloquent gliomas improves the resection rates and enables a significantly higher predictability of the resection extent. Moreover, good functional outcome can be achieved whilst operating closer to primary motor areas. Neuro-Oncology 17:v214–v220, 2015. doi:10.1093/neuonc/nov235.13 Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
The developmental and evolutionary origins of psychological essentialism lie in sortal object individuation
Authors: Hannes Rakoczy, Trix Cacchione
Journal: Behavioral and Brain Sciences (2014)

Abstract Cimpian &amp; Salomon (C&amp;S) present promising steps towards understanding the cognitive underpinnings of adult essentialism. However, their approach is less convincing regarding ontogenetic and evolutionary aspects. In contrast to C&amp;S's claim, the so-called inherence heuristic, though perhaps vital in adult reasoning, seems an implausible candidate for the developmental and evolutionary foundations of psychological essentialism. A more plausible candidate is kind-based object individuation that already embodies essentialist modes of thinking and that is present in infants and nonhuman primates.
Predicting Venous Thromboembolism in Pediatric Trauma Patients
Authors: Piyush Kalakoti, Christina Notarianni, Anil Nanda
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal